Pomi-T and PSA: a promising six-month blend trial still cannot answer the big questions
Pomi-T slowed the percentage rise in PSA in one randomized trial, but it did not prove longer survival or validate every pomegranate, tea, broccoli, and turmeric blend.

One specific four-food blend changed short-term PSA progression, but PSA is a marker—not proof of delayed metastasis, avoided treatment, or longer life.
This is stronger evidence than a single-ingredient story
Pomi-T is unusual in the supplement conversation because a randomized, double-blind, placebo-controlled trial tested the finished four-ingredient blend. The capsule combined pomegranate, green tea, broccoli, and turmeric. That makes the result more relevant to this particular formulation than studies of the ingredients separately.
The trial also has an important boundary: it followed PSA for six months. PSA can help track prostate cancer, but a slower rise is not automatically the same as fewer metastases, delayed symptoms, or longer survival. The result deserves attention without being stretched beyond what the study measured.
What the randomized study reported
Investigators randomized 199 men, average age 74, in a two-to-one ratio to the supplement or placebo. Sixty percent were on primary active surveillance, while 40 percent had rising PSA after prior treatment and were being observed. The median percentage PSA rise was 14.7 percent with the blend and 78.5 percent with placebo.
The between-group difference was statistically significant. Fewer men in the supplement group chose to leave surveillance during the study. However, treatment decisions can be influenced by PSA readings and anxiety, and the trial did not show that the blend prevented progression on imaging or pathology.

A blend result cannot identify the active part
Because all four food concentrates were given together, the trial cannot tell whether one ingredient, several ingredients, or their interaction produced the PSA difference. It also cannot validate another brand with different extracts, amounts, testing, or absorption. Ingredient name matching is not formulation matching.
This is especially relevant here because pomegranate, green tea, broccoli compounds, and curcumin each have separate prostate research. Combining familiar names may look comprehensive, but the evidence belongs to the exact product and protocol studied. A custom stack is a new intervention.
Other blend studies show why replication matters
A separate phase II study tested a different multi-ingredient product in men with biochemical recurrence. Its primary endpoint was a 50 percent PSA decline, and the formulation was not Pomi-T. A later randomized pilot of another turmeric, resveratrol, green-tea, and broccoli blend enrolled only 22 men.
These studies demonstrate continued interest, not interchangeability. Different populations, endpoints, and formulations can produce different answers. A systematic review of phytotherapy trials concluded that evidence was insufficient for definitive recommendations. Larger, longer trials tied to progression and treatment outcomes remain the need.

Use the result without letting PSA run the whole decision
If you are considering Pomi-T or a similar blend, show the exact label to the urology or oncology team. Ask about liver effects, medicine interactions, and whether the product could complicate interpretation of PSA trends. Never change an active-surveillance schedule because a supplement appears to lower the number.
The balanced conclusion is encouraging but narrow: one well-designed short trial found a favorable PSA signal from a specific blend. It did not establish cancer control or survival. Keep biopsies, imaging, PSA timing, and treatment thresholds in the shared plan, then treat the supplement discussion as an added question—not a replacement plan.
The surveillance setting raises a special responsibility
Active surveillance is not doing nothing. It is a structured strategy using repeated PSA tests, examinations, imaging, and sometimes biopsies to detect signs that treatment is becoming more appropriate. A supplement that changes PSA without changing the cancer could complicate the signal clinicians use, even when the number moves in a reassuring direction.
That possibility is not proof of harm, but it explains why the urology team should know about the product and its start date. Record the exact formulation and keep test timing consistent. A supplement decision is safest when it fits inside the surveillance protocol rather than quietly changing one of the measurements the protocol depends on. Keep copies of the label because formulations can change while the brand name stays the same.
Also report missed doses and product changes. Those details help the team avoid attributing every PSA movement to the cancer or to the supplement.